Prevalence of Post COVID-19 condition in SARS-Cov-2 infection patients at 3 months follow up in Chaiya Hospital, Surat Thani
Keywords:
Post acute COVID Syndrome, SARS-CoV-2, Prevalence, risk factors of malignancy, Long COVIDAbstract
Background: Post-acute COVID Syndrome (Long COVID) is defined as when a patient has recovered from the acute phase of the coronavirus disease 2019 but still has physical and/or mental symptoms which occur at 12 weeks after infection.
Objective: This study aimed to explore the prevalence and factors associated with Long COVID.
Method: Analytical cross-sectional research was conducted in patient databased recorded in HOSxP at Chaiya Hospital, Surat-Thani from January 2021-August 2022.
Results: The prevalence of symptoms after 12 weeks of acute covid-19 infection was dyspnea (4 %), insomnia (2 %), dry cough (1.3%), fatigue (1.3%). and 9.1 % had at least one symptom of long covid at 12 weeks follow up. It was found that prevalence of long covid occurred in female more than male (11.9% vs 5.0% p-value = .042).Patients with underlying Diabetes millitus are more likely to develop symptoms than others NCD (Hypertension, old myocardial infarction, stroke, primary hyperthyroid) at 20.7% vs 7.9 % (p-value = .023).History of covid-19 vaccination can decrease symptom of long covid by only 1.1% of vaccinated patients got long covid at 12 weeks follow- up (p-value = .002). And finally we found that old age patients (40-59 years and 59 years and over) will develop more long covid symptom than patient age 18-39 years (p=.001,p=.044).
Conclusion: The prevalence of Long COVID with at least one residual symptom was noticed. Common symptoms included dyspnea, insomnia, dry cough and fatigue. Factors associated with Long COVID syndrome were sex, in which female were found more than male, Diabetic patients and older age will develop more long covid symptom and the most important analysis data is covid vaccination can decrease long covid symptom. According to the study results, patients infected with the coronavirus 2019 suffer from Long-COVID-19. The public health system should provide surveillance, screening, and monitoring of patient symptoms, advise on observing symptoms after hospital discharged, and provide medical services.
References
World Health Organization. A clinical case definition of post COVID-19 condition by a Delphi consensus, 6 October 2021 [Internet]. October 2021 [cited 2022 Sep 1]. Available from: https://www.who.int/publications/i/item/WHO-2019-nCoV-Post_COVID-19_condition-Clinical_case_definition-2021.1
The National Institute for Health and Care Excellence. COVID-19 rapid guideline: managing the long-term effects of COVID-19 [Internet]. November 2021 [cited 2022 Sep 1]. Available from: https://www.nice.org.uk/guidance/ng188.
Augustin M, Schommers P, Stecher M, Dewald F, Gieselmann L, Gruell H, et al. PostCOVID syndrome in non-hospitalised patients with COVID-19: a longitudinal prospective cohort study. Lancet Reg Heal - Eur [Internet]. 2021 Jul 1 [cited 2021 Oct 21];6:100122. Available from: http://www.thelancet.com/article/S2666776221000995/fulltext
Menges D, Ballouz T, Anagnostopoulos A, Aschmann HE, Domenghino A, Fehr JS, et al. Burden of post-COVID-19 syndrome and implications for healthcare service planning: A population-based cohort study. PLoS One [Internet]. 2021 Jul 1 [cited 2021 Oct 21];16(7):e0254523. Available from: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0254523
Moreno-Pérez O, Merino E, Leon-Ramirez JM, Andres M, Ramos JM, Arenas-Jiménez J, et al. Post-acute COVID-19 syndrome. Incidence and risk factors: A Mediterranean cohort study. J Infect [Internet]. 2021 Mar 1 [cited 2021 Oct 21];82(3):378–83. Available from: http://www.journalofinfection.com/article/S0163445321000098/fulltext
Huang C, Huang L, Wang Y, Li X, Ren L, Gu X, et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet [Internet]. 2021 Jan 16 [cited 2021 Oct 22];397(10270):220–32. Available from: https://pubmed.ncbi.nlm.nih.gov/33428867/
Xiong Q, Xu M, Li J, Liu Y, Zhang J, Xu Y, et al. Clinical sequelae of COVID-19 survivors in Wuhan, China: a single-centre longitudinal study. Clin Microbiol Infect [Internet]. 2021 Jan 1 [cited 2021 Dec 29;27189–95.Available from: http://www.clinicalmicrobiologyandinfection.com/article/S1198743X20305759/fulltext
Huang L, Yao Q, Gu X, Wang Q, Ren L, Wang Y, et al. 1-year outcomes in hospital survivors with COVID-19: a longitudinal cohort study. Lancet [Internet]. 2021 Aug 28 [cited 2021 Oct 22];398(10302):747–58. Available from: https://pubmed.ncbi.nlm.nih.gov/34454673/
Liang L, Yang B, Jiang N, Fu W, He X, Zhou Y, et al. Three-month Follow-up Study of Survivors of Coronavirus Disease 2019 after Discharge. J Korean Med Sci [Internet]. 2020 Jan 1 [cited 2021 Oct 22];35(46). Available from: https://pubmed.ncbi.nlm.nih.gov/33289374/
USA facts Bureau’s Household Pulse, Here are the ages likely to get long covid [Internet].july 2023 [cited 2023 Sep 4]. Available from: https://usafacts.org/articles/here-are-the-ages-likely-to-get-long-covid/
กรมวิทยาศาสตร์การแพทย์. การเฝ้าระวังการระบาด และกลายพันธุ์โควิด-19 ในประเทศไทย 6 ส.ค.2564 [Internet]. กรุงเทพมหานคร; 2021. Available from: http://msto.dmsc.moph.go.th/login/showimgdetil.php?id=329
Hu Z, Huang X, Zhang J, Fu S, Ding D, Tao Z. Differences in Clinical Characteristics Between Delta Variant and Wild-Type SARS-CoV-2 Infected Patients. Front Med [Internet]. 2022;8. Available from: https://www.frontiersin.org/article/10.3389/fmed.2021.792135
Geddes L. Nine factors that could boost your risk of Long COVID.[Internet]. 2022.[cited 2022 May 5]. Available from: https://www.gavi.org/vaccineswork/nine-factors-could-boost-your-risk-longcovid
Verity R, Okell LC, Dorigatti I, Winskill P, Whittaker C, Imai N, et al. Estimates of the severity of coronavirus disease 2019: a model-based analysis. Lancet Infect Dis. 2020;20(6):669–77.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Region11Medical Journal
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.